Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterized by auto-Ab production and predominant T-cell infiltration, resulting in excessive fibrosis within the skin and internal organs. 1 The various cytokines and chemokines produced by the activated T cells contribute to recruiting additional inflammatory cells and to fibroblast activation, which promote extracellular matrix production and fibrosis.
1 SSc has been related to a Th1/Th2 dysregulation, with increase in tissue expression and in circulating Th2 cytokine levels, namely interleukin (IL)-4, IL-13 and IL-10. 2 Increased serum levels of IL-2, IL-6, TNF-α, IL-8 and monocyte chemoattractant protein (MCP)-1 were also found in SSc patients. [2] [3] [4] Although transforming growth factor (TGF)-β is one of the key mediators of increased collagen synthesis, TGF-β plasma levels did not appear to be increased in SSc patients. 4 Among the endothelial markers analyzed in SSc patients, serum levels of E-selectin and P-selectin, 5 as well as of vascular endothelial growth factor (VEGF) and of PDGF 6 were found to be increased. Therefore, the question remains if monitoring patients' serum cytokine profiles could be of help during routine clinical follow-up.
Over the past 20 years, autologous hematopoietic stem cell transplantation (aHSCT) has emerged as a new effective therapy for severe rapidly progressive diffuse cutaneous SSc (dcSSc). The early phase II studies showed that aHSCT allowed regression of skin and lung fibrosis.
7 Then, the European Society for Blood and Marrow Transplantation (EBMT)-European League Against Rheumatism (EULAR)-randomized Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial demonstrated that aHSCT conferred significant long-term overall and event-free survival benefit in dSSc patients when compared with cyclophosphamide conventional therapy. 8 After aHSCT, the immune reconstitution process in SSc patients is characterized by the reemergence of naive B cells and T cells, and resetting of the immune system, 9 with progressive increases in the regulatory T-cell numbers 10 and in Th1/Th2 cell ratio.
11
The present study was designed to analyze the serum levels of the inflammatory cytokines (IL-2, IL-6, IL-8 and interferon (IFN)-γ), the pro-fibrotic molecules (TGF-β, IL-4 and PDGF), the pro-angiogenic factors (VEGF and PDGF), the endothelial markers (E-selectin and P-selectin) and the MCP-1 chemokine before and up to 4 years after aHSCT in 20 dcSSc patients (10 male, mean age 41 ± 12 years), and if this reflect the clinical evolution.
Written informed consent was obtained and each protocol approved by the local ethics committees of the participating institutes. The aHSCT procedure at Saint-Louis Hospital (Paris, France; n = 8 patients) and LUMC Hospital (Netherlands; n = 12 patients), and follow-up were performed as described. 12 Skin fibrosis was measured by the modified Rodnan skin score (mRSS) and a decline in mRSS after aHSCT considered significant if over 25% from baseline values before transplant. 12 Control sera were collected from 18 healthy donors of the same age range as SSc patients, recruited by the Etablissement Français du Sang after informed consent.
Venous blood samples (10 ml) were taken in vacutainer tubes under sterile conditions from patients before (M0), and at 6, 12, 24, 36 and 48 months (M) after aHSCT. Results were compared with healthy control values. After clot formation, the samples were spun in a refrigerated centrifuge (3500 rpm, 15 min). The serum was quickly frozen at − 70°C and stored until assayed. Serum TGF-β1, PDGF, E-selectin and P-selectin were measured using specific ELISAs from R&D Systems (Quantikine, R&D Systems, Abingdon, UK). Serum IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α, VEGF and MCP-1 levels were determined by using BD CBA bead-based immunoassays (human specific cytokine Flex Sets; BD Cytometric Bead Array (CBA) Flex, BD Biosciences, Le Pont de Claix, France). Abbreviations: IFN = interferon; IL = interleukin; MCP = monocyte chemoattractant protein; SSc = systemic sclerosis; TGF = transforming growth factor; VEGF = vascular endothelial growth factor.
The ELISA assays detection limits were 15.6 pg/mL for TGF-β1, 15 pg/mL for PDGF and 0.5 ng/mL for E-selectin. Before aHSCT, disease duration was 4 ± 3 years and mRSS was 26 ± 3.2 (n = 20). After aHSCT, there was a significant fall in skin score to 15 ± 2.6 at M6 (Po 0.0001) persistent until M48 (9 ± 2.6, P o0.001), with sustained mRSS decreasing slope (linear regression slope = − 3.1).
Pretransplant serum cytokine levels were compared with healthy control serum levels ( Table 1 ). The IL-4, IL-6, IL-10 and IFN-γ levels in most of the tested serum samples were at the detection limits of the assays, with no significant difference between dcSSc and controls. Of interest, dcSSc patients before aHSCT had significantly higher serum levels of IL-6 (1.25-fold), IL-8 (14-fold), IL-10 (7.8-fold) and IFN-γ (3.5 fold) compared with healthy controls. The serum levels of IL-2 and VEGF were also increased in dcSSc patients, although not significantly compared with controls, although no difference in TNF-α was observed (Table 1) . TGF-β1 levels were similar in dcSSc patients and healthy controls before aHSCT ( Table 1) . The PDGF, E-selectin and P-selectin serum levels did not differ in dcSSc patients compared with healthy controls, nor did VEGF serum levels ( Table 1 ). The serum level of MCP-1 chemokine was significantly increased by 1.9-fold in dcSSc patients before transplant as compared with controls (Table 1) .
After aHSCT, the respective pretransplant increases in IL-6, IL-10 and IFN-γ serum levels, as well as the TNF-α levels detected in dcSSc patients did not change significantly (data not shown). The serum IL-2 levels decreased significantly in all dcSSc patients at 6 months compared with baseline ( Figure 1a) . Thereafter, IL-2 levels progressively increased and returned to pretransplant levels at M12 until the end of follow-up. Throughout the follow-up, IL-8 levels appeared lower than before aHSCT, with Serum cytokine levels were analyzed using the normality test. The Mann-Whitney U and Student t-test were used to compare the mean values of cytokines between patients and control subjects. *P o0.05.
high inter-individual variations and no significant difference compared with M0 ( Figure 1b) . After aHSCT, TGF-β1 levels decreased slightly but significantly at M6 compared with M0 (Figure 1c) , whereas from M12 until M48 values were similar to M0. The PDGF levels (n = 8) decreased significantly at M6, and reverted partially towards baseline values from M12 up to M48 after aHSCT (Figure 1d) . A significant decrease of VEGF serum levels was noted at M24 compared with pretransplant values (Figure 1e) . A slight but non-significant decrease in P-selectin levels (n = 8) occured until M48, whereas serum E-selectin levels (n = 16) did not vary (data not shown). The chemokine MCP-1 serum levels remained elevated at M6 and decreased progressively thereafter with a constant slope of 0.03 log/month up to M48 (Figure 1f ).
An abnormal immune response is central to SSc physiopathology, with dysregulation in the various cytokines, chemokines and growth factors production by T lymphocytes, monocytes and other inflammatory cells, all contributing to tissue fibrosis.
1 High levels of IL-2, IL-6, IL-8, MCP-1 and IFN-γ observed in SSc patients before aHSCT reflect their inflammatory clinical status, 2, 13, 14 and IL-10 levels support a predominant Th2 immune response. As already reported, 3 we found very low pro-fibrotic IL-4 and IL-13 serum levels in SSc patients.
After aHSCT, we confirmed significant regression of skin fibrosis. 7, 8, 12 The decrease in IL-2 and IL-8 levels, slight but significant decrease in TGF-β levels at M6, along with fall in mRSS may reflect downregulation of SSc fibroblast activation with a lower inflammatory status after aHSCT in dcSSc patients. Nonetheless, we show that repeated measures of TGF-β serum levels did not reflect the skin score regression post transplant.
MCP-1 contributes to dermal fibrosis through multiple pathways, including enhanced fibroblast proliferation and collagen production. 1, 3 We showed that MCP-1 levels reduced subsequently to the transplant with progressive decrease along the 48 months after transplant, meanwhile clinical regression of skin fibrosis was sustained.
PDGF is linked to wound healing and fibrosis, and the presence of stimulatory Abs to PDGFR has been proposed as a specific hallmark of scleroderma. 1 Within the limits of our study, we found no increase in circulating levels of PDGF before transplant, but a significant fall at 6 months after aHSCT. A slight decrease in VEGF serum levels was observed after aHSCT, which merits further exploration, as chronic and uncontrolled VEGF upregulation has been related to abnormal vessel morphology and endothelium in SSc. 15 Despite the increased levels of IL-6, IL-8, IL-10 and IFN-γ at baseline, these cytokines levels were not clinically meaningful and did not fall after transplant. Apart from changes in serum MCP-1 levels, the other serum cytokine levels analyzed herein did not appear as relevant markers of SSc clinical evolution. Polymorphism-induced alterations on the cytokine gene or on its receptors might have a role in SSc pathogenesis and could be more reliable markers to be studied when combined to cytokine dosages. 2 In conclusion, the increase in pro-fibrotic and Th2 cytokine serum levels in severe SSc patients was only partly reversed after aHSCT, whereas significant regression of clinical skin fibrosis was sustained up to 4 years after transplant. Further studies using new techniques with little blood sampling allowing rapid and multiple cytokine dosages at low cost are warranted on a larger number of patients. They would allow us to further determine if patient serum cytokine profiles before and after aHSCT can be of value for better SSc patients' follow-up, and immune monitoring in light of clinical response and immunosuppressive drug requirement. Among these cytokines, the prognostic value of C-X-C motif chemokine ligand 4 (CXCL4), recently described in the pathogenesis of SSc, 16 may be relevant marker to study before and after transplant.
